[Federal Register Volume 69, Number 171 (Friday, September 3, 2004)]
[Notices]
[Page 53930]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-20093]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Antitumor Macrocyclic 
Lactones, Compositions and Methods of Use

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR part 404.7(a)(1)(i), that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive patent license to practice the inventions embodied in 
International Patent Application PCT/US98/15011, all related foreign 
and domestic patents and patent applications, entitled ``Antitumor 
Macrocyclic Lactones, Compositions and Methods of Use'' (DHHS Ref. No. 
E-244-1997/0), and in International Patent Application PCT/US00/05582, 
all related foreign and domestic patents and patent applications, 
entitled ``Vacuolar-Type (H+)-ATPase Inhibiting Compounds, 
Compositions, And Use Thereof '' (DHHS Ref. No. E-244-1997/3), to Reata 
Discovery, Inc., located in Dallas, TX. The patent rights in these 
inventions have been assigned to the United States of America.
    The prospective exclusive license territory will be worldwide and 
the field of use may be limited to human therapeutics for the treatment 
of cancer.

DATES: Only written comments and/or license applications which are 
received by the National Institutes of Health on or before November 2, 
2004 will be considered.

ADDRESSES: Requests for copies of the patent, inquiries, comments and 
other materials relating to the contemplated exclusive license should 
be directed to: George G. Pipia, PhD, Technology Licensing Specialist, 
Office of Technology Transfer, National Institutes of Health, 6011 
Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: 
(301) 435-5560; Facsimile: (301) 402-0220; and e-mail: 
[email protected].

SUPPLEMENTARY INFORMATION: The present inventions include macrocyclic 
lactones, and specifically salicylihalamides and related compounds, 
which are among the classes of compounds identified from biological 
sources. The NIH licensee for this technology might have some 
obligations to the source-country of the biological material. The 
present inventions further provide a method of preventing or treating 
cancer, which comprises administration to a patient an effective 
anticancer amount of at least one compound of the present invention. 
Furthermore, these compounds act as vacuolar-type (H+)-ATP-
ase inhibitors and can possibly be useful for the treatment of 
osteoporosis, development of drug resistance in tumor cells, 
Alzheimer's disease, glaucoma, abnormal urinary acidification and 
treatment or prevention of viral infections (e.g., baculoviruses and 
retroviruses).
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 
404.7. The prospective exclusive license may be granted unless within 
sixty (60) days from the date of this published notice, the NIH 
receives written evidence and argument that establish that the grant of 
the license would not be consistent with the requirements of 35 U.S.C. 
209 and 37 CFR part 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: August 25, 2004.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 04-20093 Filed 9-2-04; 8:45 am]
BILLING CODE 4140-01-P